Cellectar Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Cellectar Biosciences, Inc. (CLRB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.25 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 3.25M shares, a 332.15% increase year-over-year.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 3.26M shares, a 206.12% increase year-over-year.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 2.21M shares, a 108.92% increase year-over-year.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 750.92K shares, a 30.38% increase year-over-year.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 3.26M shares, a 284.18% increase from fiscal 2024.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 849.03K shares, a 97.42% decline from fiscal 2023.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 32.90M shares, a 334.51% increase from fiscal 2022.
- Cellectar Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.57M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 3.25M shares 10-Q · filed 2026-08-13 | 3.25M shares 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | 3.26M shares 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | 3.26M shares 10-K · filed 2026-03-04 | |||||||
| 2025-09-30 | 2.21M shares 10-Q · filed 2025-11-13 | 2.21M shares 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | 750.92K shares 10-Q · filed 2026-08-13 | 750.92K shares 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | 1.07M shares 10-Q · filed 2026-05-14 | 31.97M shares 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | 849.03K shares 10-K · filed 2026-03-04 | 25.47M shares 10-K · filed 2025-03-13 | ||||||
| 2024-09-30 | 1.06M shares 10-Q · filed 2025-11-13 | 31.79M shares 10-Q · filed 2024-11-18 | 1.06M shares 10-Q · filed 2025-11-13 | 31.79M shares 10-Q · filed 2024-11-18 | ||||
| 2024-06-30 | 575.95K shares 10-Q · filed 2025-08-14 | 17.28M shares 10-Q · filed 2024-10-29 | 715.99K shares 10-Q · filed 2025-08-14 | 21.48M shares 10-Q · filed 2024-10-29 | ||||
| 2024-03-31 | 21.56M shares 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | 32.90M shares 10-K · filed 2025-03-13 | 33.98M shares 10-K · filed 2024-03-27 | ||||||
| 2023-09-30 | 29.54M shares 10-Q · filed 2024-11-18 | 29.54M shares 10-Q · filed 2024-11-18 | ||||||
| 2023-06-30 | 9.04M shares 10-Q · filed 2024-10-29 | 9.04M shares 10-Q · filed 2024-10-29 | ||||||
| 2023-03-31 | 8.30M shares 10-Q/A · filed 2024-10-29 | |||||||
| 2022-12-31 | 7.57M shares 10-K/A · filed 2024-10-29 | |||||||
| 2022-09-30 | 2.33M shares 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | 2.33M shares 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | 2.28M shares 10-Q · filed 2023-05-04 | |||||||
| 2021-09-30 | 2.77M shares 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |